Abstract:Capture of endothelial progenitor cells (EPCs) in situ has been considered as a promising strategy for the rapid endothelialization and long-term patency of artificial blood vessels and implant devices. In this study, a CD133+ EPC capture surface was fabricated by grafting CD133 antibody (a more specific EPC surface marker than CD34) and Arg-Glu-Asp-Val (REDV) peptideon the methacrylate-grafted hyaluronic acid (MA-HA) and heparin-hybridized (MA-HA&Heparin) resisting layer. Vascular endothelial growth factor (VEGF) was further conjugated to the immobilized heparin. This engineered surface showed good hemocompatibility and significantly higher ability of capturing CD133+ EPCs from human peripheral blood mononuclear cells (PBMCs) and obviously upregulated the expression of endothelial cell (EC) marker genes of EPCs such as VEGF receptor 2 (VEGFR2), CD31, VE-cadherin, and von Willebrand factor (vWF), facilitating the differentiation of EPCs into ECs. The dramatically enhanced EPC proliferation on this surface was dependent on the integrin-VEGFR synergistic signaling, as ERK1/2 phosphorylation was only significantly enhanced on the REDV and VEGF co-immobilized surface. This study highlights a new surface coating strategy for blood-contact materials based on the specific EPC capturing and rapid endothelialization. STATEMENT OF SIGNIFICANCE: Capture of endothelial progenitor cells (EPCs) in situ is a promising strategy for the rapid endothelialization and long-term patency of artificial blood vessels and scaffolds. More specific capture of EPCs by targeting CD133 rather than CD34 can better reduce the risk of inflammation and restenosis. On the other hand, an appropriate microenvironment for EPC proliferation is equally important for endothelialization, which is rarely considered by the existing EPC capture strategies. In this study, the capture ratio of EPCs was significantly increased by simultaneously grafting CD133 antibody and VEGF on a MA-HA and heparin-hybridized antifouling layer. Further, proliferation of EPCs after capture was significantly promoted by grafting VEGF and REDV peptide through the integrin-VEGFR synergistic signaling. This study highlights a new strategy for the surface coating of blood-contact materials based on specific EPC capture and rapid endothelialization.

The promotion of tissue engineering blood vessel patency by CGS21680 through regulating pro-inflammatory activities of endothelial progenitor cell.

Highly Efficient Local Delivery of Endothelial Progenitor Cells Significantly Potentiates Angiogenesis and Full-Thickness Wound Healing.

Infusion of Endothelial Progenitor Cells Accelerates Hematopoietic and Immune Reconstitution, and Ameliorates the Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation

Construction of Tissue-Engineered Vascular Grafts with Enhanced Patency by Integrating Heparin, Cell-Adhesive Peptide, and Carbon Monoxide Nanogenerators into Acellular Blood Vessels

Effect of HMGB1 on the Paracrine Action of EPC Promotes Post-Ischemic Neovascularization in Mice.

Construction of Tissue-Engineered Vascular Grafts with High Patency by Mimicking Immune Stealth and Blocking TGF-β Mediated Endothelial-to-mesenchymal Transition

Regulation of Macrophage Polarization and Promotion of Endothelialization by NO Generating and PEG-YIGSR Modified Vascular Graft.

Administration of in vitro expanded bone marrow-derived endothelial progenitor cells (EPCs) contribute to the development of neointimal thickenings in mouse aortic allografts

Functionalization of in Vivo Tissue-Engineered Living Biotubes Enhance Patency and Endothelization Without the Requirement of Systemic Anticoagulant Administration.

The effect of stromal cell-derived factor-1α/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration.

Tailored Endothelialization Enabled by Engineered Endothelial Cell Vesicles Accelerates Remodeling of Small-Diameter Vascular Grafts

The relationship between the inflammatory response and cell adhesion on alginate-chitosan-alginate microcapsules after transplantation.

The Use of BDNF to Enhance the Patency Rate of Small-Diameter Tissue-Engineered Blood Vessels Through Stem Cell Homing Mechanisms.

Co-immobilization of CD133 Antibodies, Vascular Endothelial Growth Factors, and REDV Peptide Promotes Capture, Proliferation, and Differentiation of Endothelial Progenitor Cells.

A Novel Scaffold for Endothelial Progenitor Cells in Tissue Engineered Vascular Grafts

VEGF Combined with DAPT Promotes Tissue Regeneration and Remodeling in Vascular Grafts.

The effect of endothelial progenitor cells transplantation on microenvironments in a murine model of chronic vein thrombosis

Evaluation of Interleukin-4-Loaded Sodium Alginate-Chitosan Microspheres for Their Support of Microvascularization in Engineered Tissues.

Development of transgenic endothelial progenitor cell-seeded stents.

Differentiation of smooth muscle progenitor cells in peripheral blood and its application in tissue engineered blood vessels

Multifunctional nanoparticle-VEGF modification for tissue-engineered vascular graft to promote sustained anti-thrombosis and rapid endothelialization